Journal for ImmunoTherapy of Cancer: 4 (1)

Basic Tumor Immunology

Fusion of the dendritic cell-targeting chemokine MIP3α to melanoma antigen Gp100 in a therapeutic DNA vaccine significantly enhances immunogenicity and survival in a mouse melanoma model (20 December, 2016)
James T. Gordy, Kun Luo, Hong Zhang, Arya Biragyn, Richard B. Markham
Classical and non-classical HLA class I aberrations in primary cervical squamous- and adenocarcinomas and paired lymph node metastases (15 November, 2016)
Debbie M. Ferns, A. Marijne Heeren, Sanne Samuels, Maaike C. G. Bleeker, Tanja D. de Gruijl, Gemma G. Kenter, Ekaterina S. Jordanova
Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide (18 October, 2016)
Genevieve M. Weir, Olga Hrytsenko, Tara Quinton, Neil L. Berinstein, Marianne M. Stanford, Marc Mansour
Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor associated macrophages – a self-amplifying, CD39- and CD73-dependent mechanism for tumor immune escape (16 August, 2016)
Itsaso Montalbán del Barrio, Cornelia Penski, Laura Schlahsa, Roland G. Stein, Joachim Diessner, Achim Wöckel, Johannes Dietl, Manfred B. Lutz, Michel Mittelbronn, Jörg Wischhusen, Sebastian F. M. Häusler
Pancreatic cancer stem cells in patient pancreatic xenografts are sensitive to drozitumab, an agonistic antibody against DR5 (21 June, 2016)
Jason W.-L. Eng, Thomas A. Mace, Rohit Sharma, Danielle Y. F. Twum, Peng Peng, John F. Gibbs, Rosemarie Pitoniak, Chelsey B. Reed, Scott I. Abrams, Elizabeth A. Repasky, Bonnie L. Hylander
Enhanced recruitment of genetically modified CX3CR1-positive human T cells into Fractalkine/CX3CL1 expressing tumors: importance of the chemokine gradient (19 April, 2016)
Imran Siddiqui, Marco Erreni, Mandy van Brakel, Reno Debets, Paola Allavena
Monomeric annexin A2 is an oxygen-regulated toll-like receptor 2 ligand and adjuvant (16 February, 2016)
Brian M. Andersen, Junzhe Xia, Alan L. Epstein, John R. Ohlfest, Wei Chen, Bruce R. Blazar, Christopher A. Pennell, Michael R. Olin
Mismatch in epitope specificities between IFNγ inflamed and uninflamed conditions leads to escape from T lymphocyte killing in melanoma (16 February, 2016)
Katherine Woods, Ashley J. Knights, Matthew Anaka, Ralf B. Schittenhelm, Anthony W. Purcell, Andreas Behren, Jonathan Cebon
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8⁺ T cells without host preconditioning
(16 February, 2016)
Michelle H. Nelson, Jacob S. Bowers, Stefanie R. Bailey, Marshall A. Diven, Caroline W. Fugle, Andrew D. M. Kaiser, Claudia Wrzesinski, Bei Liu, Nicholas P. Restifo, Chrystal M. Paulos

Case Report

Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report & review of the literature (20 December, 2016)
Joshua E. Reuss, Paul R. Kunk, Anne M. Stowman, Alejandro A. Gru, Craig L. Slingluff, Elizabeth M. Gaughan
Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy (20 December, 2016)
Jared R. Lowe, Daniel J. Perry, April K. S. Salama, Clayton E. Mathews, Larry G. Moss, Brent A. Hanks
PD1/PD-L1 inhibition as a potential radiosensitizer in head and neck squamous cell carcinoma: a case report (15 November, 2016)
Misako Nagasaka, Mark Zaki, Harold Kim, S. Naweed Raza, George Yoo, Ho-sheng Lin, Ammar Sukari
Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy– a report of two cases (15 November, 2016)
Bhaskar C. Kolla, Manish R. Patel
Metastatic Merkel cell carcinoma response to nivolumab (15 November, 2016)
Frances M. Walocko, Benjamin Y. Scheier, Paul W. Harms, Leslie A. Fecher, Christopher D. Lao
Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810 (15 November, 2016)
Gerald S. Falchook, Rom Leidner, Elizabeth Stankevich, Brian Piening, Carlo Bifulco, Israel Lowy, Matthew G. Fury
Acute visual loss after ipilimumab treatment for metastatic melanoma (18 October, 2016)
Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection (18 October, 2016)
Michael Ong, Andrea Marie Ibrahim, Samuel Bourassa-Blanchette, Christina Canil, Todd Fairhead, Greg Knoll
Urothelial carcinoma of donor origin in a kidney transplant patient (18 October, 2016)
Rosa M. Michel Ortega, Daynna J. Wolff, Cynthia A. Schandl, Harry A. Drabkin
Increased FDG avidity in lymphoid tissue associated with response to combined immune checkpoint blockade (20 September, 2016)
Katy K. Tsai, Miguel H. Pampaloni, Charity Hope, Alain P. Algazi, Britt-Marie Ljung, Laura Pincus, Adil I. Daud
A case report of Grover’s disease from immunotherapy-a skin toxicity induced by inhibition of CTLA-4 but not PD-1 (20 September, 2016)
Marc Uemura, Faisal Faˈak, Cara Haymaker, Natalie McQuail, Elizabeth Sirmans, Courtney W. Hudgens, Lydia Barbara, Chantale Bernatchez, Jonathan L. Curry, Patrick Hwu, Michael T. Tetzlaff, Adi Diab
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy (16 August, 2016)
Lucie Heinzerling, Patrick A. Ott, F. Stephen Hodi, Aliya N. Husain, Azadeh Tajmir-Riahi, Hussein Tawbi, Matthias Pauschinger, Thomas F. Gajewski, Evan J. Lipson, Jason J. Luke
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy (16 August, 2016)
Viktor H. Koelzer, Tobias Buser, Niels Willi, Sacha I. Rothschild, Andreas Wicki, Peter Schiller, Gieri Cathomas, Alfred Zippelius, Kirsten D. Mertz
Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody (21 June, 2016)
Mehmet Asim Bilen, Sumit K. Subudhi, Jianjun Gao, Nizar M. Tannir, Shi-Ming Tu, Padmanee Sharma
Tumor control with PD-1 inhibition in a patient with concurrent metastatic melanoma and renal cell carcinoma (19 April, 2016)
Melina E. Marmarelis, Meredith R. Davis, Nilay S. Sethi, Katherine M. Krajewksi, Rana R. McKay, Toni K. Choueiri, Patrick A. Ott
Disease stabilization with pembrolizumab for metastatic acral melanoma in the setting of autoimmune bullous pemphigoid (19 April, 2016)
Kristen M. Beck, Joanna Dong, Larisa J. Geskin, Vincent P. Beltrani, Richard G. Phelps, Richard D. Carvajal, Gary Schwartz, Yvonne M. Saenger, Robyn D. Gartrell
Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study (15 March, 2016)
Viktor H. Koelzer, Sacha I. Rothschild, Deborah Zihler, Andreas Wicki, Berenika Willi, Niels Willi, Michèle Voegeli, Gieri Cathomas, Alfred Zippelius, Kirsten D. Mertz
Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab (16 February, 2016)
Matthew Zibelman, Natasha Pollak, Anthony J Olszanski

Clinical Trials Monitor

Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy (20 September, 2016)
Hasan Rehman, Ann W. Silk, Michael P. Kane, Howard L. Kaufman
Current clinical trials testing the combination of immunotherapy with radiotherapy (20 September, 2016)
Josephine Kang, Sandra Demaria, Silvia Formenti
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction? (16 August, 2016)
Claud Grigg, Naiyer A. Rizvi
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine (17 May, 2016)
David B. Page, Tyler W. Hulett, Traci L. Hilton, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox

Clinical/Translational Cancer Immunotherapy

A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma (20 December, 2016)
Andrew S. Brohl, Nikhil I. Khushalani, Zeynep Eroglu, Joseph Markowitz, Ram Thapa, Y. Ann Chen, Ragini Kudchadkar, Jeffrey S. Weber
Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients (20 December, 2016)
Mizuki Nishino, Nikhil H. Ramaiya, Emily S. Chambers, Anika E. Adeni, Hiroto Hatabu, Pasi A. Jänne, F. Stephen Hodi, Mark M. Awad
Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy (15 November, 2016)
Shruti Agrawal, Yan Feng, Amit Roy, Georgia Kollia, Brian Lestini
5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers (18 October, 2016)
Lauren Van Der Kraak, Gaurav Goel, Krishnaveni Ramanan, Christof Kaltenmeier, Lin Zhang, Daniel P. Normolle, Gordon J. Freeman, Daolin Tang, Katie S. Nason, Jon M. Davison, James D. Luketich, Rajeev Dhupar, Michael T. Lotze
Expansion of tumor-infiltrating lymphocytes (TIL) from human pancreatic tumors (18 October, 2016)
MacLean Hall, Hao Liu, Mokenge Malafa, Barbara Centeno, Pamela J. Hodul, José Pimiento, Shari Pilon-Thomas, Amod A. Sarnaik
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction (18 October, 2016)
Bridgette A. Kanz, Megan H. Pollack, Romany Johnpulle, Igor Puzanov, Leora Horn, Alicia Morgans, Jeffrey A. Sosman, Suthee Rapisuwon, R. Martin Conry, Zeynep Eroglu, Douglas B. Johnson
A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma (20 September, 2016)
Elizabeth I. Buchbinder, Anasuya Gunturi, Jessica Perritt, Janice Dutcher, Sandra Aung, Howard L. Kaufman, Marc S. Ernstoff, Girald P. Miletello, Brendan D. Curti, Gregory A. Daniels, Sapna P. Patel, John M. Kirkwood, Sigrun Hallmeyer, Joseph I. Clark, Rene Gonzalez, John M. Richart, Joe Lutzky, Michael A. Morse, Ryan J. Sullivan, David F. McDermott
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy of borderline resectable and locally advanced pancreatic adenocarcinoma (16 August, 2016)
Todd Crocenzi, Benjamin Cottam, Pippa Newell, Ronald F. Wolf, Paul D. Hansen, Chet Hammill, Matthew C. Solhjem, Yue-Yun To, Amy Greathouse, Garth Tormoen, Zeljka Jutric, Kristina Young, Keith S. Bahjat, Michael J. Gough, Marka R. Crittenden
Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
(16 August, 2016)
Asim Amin, David H. Lawson, April K.S. Salama, Henry B. Koon, Troy Guthrie, Sajeve S. Thomas, Steven J. O’Day, Montaser F. Shaheen, Bin Zhang, Stephen Francis, F. Stephen Hodi
Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab (21 June, 2016)
Janet Retseck, Robert VanderWeele, Hui-Min Lin, Yan Lin, Lisa H. Butterfield, Ahmad A. Tarhini
Progression-free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial (21 June, 2016)
H. J. Gray, B. Benigno, J. Berek, J. Chang, J. Mason, L. Mileshkin, P. Mitchell, M. Moradi, F. O. Recio, C. M. Michener, A. Alvarez Secord, N E. Tchabo, J. K. Chan, J. Young, H. Kohrt, S. E. Gargosky, J. C. Goh
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (17 May, 2016)
Mira A. Patel, Jennifer E. Kim, Debebe Theodros, Ada Tam, Esteban Velarde, Christina M. Kochel, Brian Francica, Thomas R. Nirschl, Ali Ghasemzadeh, Dimitrios Mathios, Sarah Harris-Bookman, Christopher C. Jackson, Christina Jackson, Xiaobu Ye, Phuoc T. Tran, Betty Tyler, Vladimir Coric, Mark Selby, Henry Brem, Charles G. Drake, Drew M. Pardoll, Michael Lim
Prolonged intralymphatic delivery of dendritic cells through implantable lymphatic ports in patients with advanced cancer (19 April, 2016)
Michal Radomski, Herbert J. Zeh, Howard D. Edington, James F. Pingpank, Lisa H. Butterfield, Theresa L. Whiteside, Eva Wieckowski, David L. Bartlett, Pawel Kalinski
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers (15 March, 2016)
Tuuli Ranki, Sari Pesonen, Akseli Hemminki, Kaarina Partanen, Kalevi Kairemo, Tuomo Alanko, Johan Lundin, Nina Linder, Riku Turkki, Ari Ristimäki, Elke Jäger, Julia Karbach, Claudia Wahle, Matti Kankainen, Charlotta Backman, Mikael von Euler, Elina Haavisto, Tiina Hakonen, Raita Heiskanen, Magnus Jaderberg, Juuso Juhila, Petri Priha, Laura Suoranta, Lotta Vassilev, Antti Vuolanto, Timo Joensuu
Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study (15 March, 2016)
Howard L. Kaufman, Thomas Amatruda, Tony Reid, Rene Gonzalez, John Glaspy, Eric Whitman, Kevin Harrington, John Nemunaitis, Andrew Zloza, Michael Wolf, Neil N. Senzer

Commentary

Advances in immunotherapeutic strategies for colorectal cancer commentary on: tumoral immune cell exploitation in colorectal cancer metastases can be targeted effectively by anti-CCR5 therapy in cancer patients by Halama et al (20 December, 2016)
Dustin A. Deming
Being “penny-wise but pound foolish” in cancer immunotherapy research: the urgent need for mouse cancer models to reflect human modifying factors (20 December, 2016)
William J. Murphy
A quantum leap in cancer vaccines? (20 December, 2016)
Eli Gilboa
Application of the Immunoscore as prognostic tool for hepatocellular carcinoma (15 November, 2016)
Annacarmen Petrizzo, Luigi Buonaguro
TCR diversity – a universal cancer immunotherapy biomarker? (15 November, 2016)
Douglas G. McNeel
Re-discovering NK cell allo-reactivity in the therapy of solid tumors (20 September, 2016)
Luca Castagna, Domenico Mavilio
Circulating protein and antibody biomarker for personalized cancer immunotherapy (16 August, 2016)
Jianda Yuan
It’s TIME for a biomarker-driven approach to cancer immunotherapy (16 August, 2016)
Leisha A. Emens
Cancer immunotherapy trials: leading a paradigm shift in drug development (19 July, 2016)
Leisha A. Emens, Lisa H. Butterfield, F. Stephen Hodi, Francesco M. Marincola, Howard L. Kaufman
NLRC5, a promising new entry in tumor immunology (19 July, 2016)
Sonia T. Chelbi, Greta Guarda
How do I steer this thing? Using dendritic cell targeted vaccination to more effectively guide the antitumor immune response with combination immunotherapy (21 June, 2016)
Stefanie N. Linch, William L. Redmond
Immune-related response evaluations during immune-checkpoint inhibitor therapy: establishing a “common language” for the new arena of cancer treatment (21 June, 2016)
Mizuki Nishino
Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? (17 May, 2016)
Sandra Demaria, Silvia C. Formenti
Targetless T cells in cancer immunotherapy (19 April, 2016)
Per thor Straten, Federico Garrido
Natural killer cell immunotherapy to target stem-like tumor cells (19 April, 2016)
Steven K. Grossenbacher, Robert J. Canter, William J. Murphy
A role for pre-mNK cells in tumor progression (15 March, 2016)
Carolyn Rosinsky, Paul Andrew Antony
Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds (16 February, 2016)
Michael Kalos

Editorial

Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule (21 June, 2016)
Howard L. Kaufman, Lisa H. Butterfield, Pierre G. Coulie, Sandra Demaria, Robert L. Ferris, Jérôme Galon, Samir N. Khleif, Ira Mellman, Pamela S. Ohashi, Willem W. Overwijk, Suzanne L. Topalian, Francesco M. Marincola

Immunotherapy Biomarkers

Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide (15 November, 2016)
Ioannis F. Voutsas, Eleftheria A. Anastasopoulou, Panagiotis Tzonis, Michael Papamichail, Sonia A. Perez, Constantin N. Baxevanis
Single dose denileukin diftitox does not enhance vaccine-induced T cell responses or effectively deplete Tregs in advanced melanoma: immune monitoring and clinical results of a randomized phase II trial (21 June, 2016)
Jason J. Luke, Yuanyuan Zha, Karen Matijevich, Thomas F. Gajewski
Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients (21 June, 2016)
Vishwajith Sridharan, Danielle N. Margalit, Stephanie A. Lynch, Mariano Severgnini, F. Stephen Hodi, Robert I. Haddad, Roy B. Tishler, Jonathan D. Schoenfeld

Meeting Report

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5^th 2015
(18 October, 2016)
Paolo A. Ascierto, Maria Libera Ascierto, Silvia Formenti, Sacha Gnjatic, Hans Hammers, Vera Hirsh, Rolf Kiessling, Ignacio Melero, Rita Nanda, Graham Pawelec, Sandro Pignata, Pedro Romero, Daniel E. Speiser, Bernard A. Fox, Francesco M. Marincola
What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO) (19 July, 2016)
Paolo Antonio Ascierto, Giacomo Cartenì, Cesare Gridelli, Sandro Pignata, Antonio Pinto, Carmen Criscitiello, Luigi Buonaguro, Stefano Pepe, Roberto Mabilia, Vincenzo Montesarchio, Bruno Daniele, Sabino De Placido
The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer (19 January, 2016)
Bruno Daniele, Bruno Sangro, Daniel Petrylak, Fabio Calabrò, Giacomo Cartenì, Vincenzo Montesarchio, Sabino De Placido, Paolo A. Ascierto

Position Articles and Guidelines

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma (20 December, 2016)
Douglas G. McNeel, Neil H. Bander, Tomasz M. Beer, Charles G. Drake, Lawrence Fong, Stacey Harrelson, Philip W. Kantoff, Ravi A. Madan, William K. Oh, David J. Peace, Daniel P. Petrylak, Hank Porterfield, Oliver Sartor, Neal D. Shore, Susan F. Slovin, Mark N. Stein, Johannes Vieweg, James L. Gulley
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia (20 December, 2016)
Michael Boyiadzis, Michael R. Bishop, Rafat Abonour, Kenneth C. Anderson, Stephen M. Ansell, David Avigan, Lisa Barbarotta, Austin John Barrett, Koen Van Besien, P. Leif Bergsagel, Ivan Borrello, Joshua Brody, Jill Brufsky, Mitchell Cairo, Ajai Chari, Adam Cohen, Jorge Cortes, Stephen J. Forman, Jonathan W. Friedberg, Ephraim J. Fuchs, Steven D. Gore, Sundar Jagannath, Brad S. Kahl, Justin Kline, James N. Kochenderfer, Larry W. Kwak, Ronald Levy, Marcos de Lima, Mark R. Litzow, Anuj Mahindra, Jeffrey Miller, Nikhil C. Munshi, Robert Z. Orlowski, John M. Pagel, David L. Porter, Stephen J. Russell, Karl Schwartz, Margaret A. Shipp, David Siegel, Richard M. Stone, Martin S. Tallman, John M. Timmerman, Frits Van Rhee, Edmund K. Waller, Ann Welsh, Michael Werner, Peter H. Wiernik, Madhav V. Dhodapkar
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma (15 November, 2016)
Brian I. Rini, David F. McDermott, Hans Hammers, William Bro, Ronald M. Bukowski, Bernard Faba, Jo Faba, Robert A. Figlin, Thomas Hutson, Eric Jonasch, Richard W. Joseph, Bradley C. Leibovich, Thomas Olencki, Allan J. Pantuck, David I. Quinn, Virginia Seery, Martin H. Voss, Christopher G. Wood, Laura S. Wood, Michael B. Atkins

Review

Canine cancer immunotherapy studies: linking mouse and human (20 December, 2016)
Jiwon S. Park, Sita S. Withers, Jaime F. Modiano, Michael S. Kent, Mingyi Chen, Jesus I. Luna, William T. N. Culp, Ellen E. Sparger, Robert B. Rebhun, Arta M. Monjazeb, William J. Murphy, Robert J. Canter
Challenges and opportunities for checkpoint blockade in T-cell lymphoproliferative disorders (20 December, 2016)
Tycel Phillips, Sumana Devata, Ryan A. Wilcox
A New VISTA on combination therapy for negative checkpoint regulator blockade (20 December, 2016)
Jie Deng, Isabelle Le Mercier, Anna Kuta, Randolph J. Noelle
Validation of biomarkers to predict response to immunotherapy in cancer: Volume II — clinical validation and regulatory considerations (15 November, 2016)
Kevin K. Dobbin, Alessandra Cesano, John Alvarez, Rachael Hawtin, Sylvia Janetzki, Ilan Kirsch, Giuseppe V. Masucci, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Jenny Zhang, Lisa H. Butterfield, Magdalena Thurin
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I — pre-analytical and analytical validation (15 November, 2016)
Giuseppe V. Masucci, Alessandra Cesano, Rachael Hawtin, Sylvia Janetzki, Jenny Zhang, Ilan Kirsch, Kevin K. Dobbin, John Alvarez, Paul B. Robbins, Senthamil R. Selvan, Howard Z. Streicher, Lisa H. Butterfield, Magdalena Thurin
Clinical significance of tumor-infiltrating lymphocytes in breast cancer (18 October, 2016)
Sasha E. Stanton, Mary L. Disis
Adjuvants for peptide-based cancer vaccines (20 September, 2016)
Hiep Khong, Willem W. Overwijk
B cell regulation of the anti-tumor response and role in carcinogenesis (19 July, 2016)
Marc Schwartz, Yu Zhang, Joseph D. Rosenblatt
From bench to bedside a comprehensive review of pancreatic cancer immunotherapy (15 March, 2016)
Paul R. Kunk, Todd W. Bauer, Craig L. Slingluff, Osama E. Rahma
Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials (15 March, 2016)
Holbrook E. Kohrt, Paul C. Tumeh, Don Benson, Nina Bhardwaj, Joshua Brody, Silvia Formenti, Bernard A. Fox, Jerome Galon, Carl H. June, Michael Kalos, Ilan Kirsch, Thomas Kleen, Guido Kroemer, Lewis Lanier, Ron Levy, H. Kim Lyerly, Holden Maecker, Aurelien Marabelle, Jos Melenhorst, Jeffrey Miller, Ignacio Melero, Kunle Odunsi, Karolina Palucka, George Peoples, Antoni Ribas, Harlan Robins, William Robinson, Tito Serafini, Paul Sondel, Eric Vivier, Jeff Weber, Jedd Wolchok, Laurence Zitvogel, Mary L. Disis, Martin A. Cheever, on behalf of the Cancer Immunotherapy Trials Network (CITN)
Metabolic communication in tumors: a new layer of immunoregulation for immune evasion (16 February, 2016)
Ping-Chih Ho, Pu-Ste Liu
Novel technologies and emerging biomarkers for personalized cancer immunotherapy (19 January, 2016)
Jianda Yuan, Priti S. Hegde, Raphael Clynes, Periklis G. Foukas, Alexandre Harari, Thomas O. Kleen, Pia Kvistborg, Cristina Maccalli, Holden T. Maecker, David B. Page, Harlan Robins, Wenru Song, Edward C. Stack, Ena Wang, Theresa L. Whiteside, Yingdong Zhao, Heinz Zwierzina, Lisa H. Butterfield, Bernard A. Fox

Short Report

High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome (18 October, 2016)
S. Chow, V. Galvis, M. Pillai, R. Leach, E. Keene, A. Spencer-Shaw, A. Shablak, J. Shanks, T. Liptrot, F. Thistlethwaite, R. E. Hawkins
Biomarkers immune monitoring technology primer: Immunoscore® Colon (20 September, 2016)
Fabienne Hermitte
Concurrent SPECT/PET-CT imaging as a method for tracking adoptively transferred T-cells in vivo (17 May, 2016)
Sasha E. Stanton, Janet F. Eary, Edmond A. Marzbani, David Mankoff, Lupe G. Salazar, Doreen Higgins, Jennifer Childs, Jessica Reichow, Yushe Dang, Mary L. Disis
Immune monitoring technology primer: whole exome sequencing for neoantigen discovery and precision oncology (19 April, 2016)
Pia Kvistborg, Raphael Clynes, Wenru Song, Jianda Yuan
Immune monitoring technology primer: immunoprofiling of antigen-stimulated blood (15 March, 2016)
Laura Rosa Brunet, Samuel LaBrie, Thorsten Hagemann
Multiplexed tissue biomarker imaging (16 February, 2016)
Edward C. Stack, Periklis G. Foukas, Peter P. Lee
Immune Monitoring Technology Primer: protein microarray (‘seromics’) (19 January, 2016)
Jianda Yuan, Ena Wang, Bernard A. Fox

Reviewer Acknowledgement

Journal for immunotherapy of cancer reviewer acknowledgement 2015 (16 February, 2016)
Pedro Romero

Erratum

Erratum to: Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma (4 November, 2016)
Mira A. Patel, Jennifer E. Kim, Debebe Theodros, Ada Tam, Esteban Velarde, Christina M. Kochel, Brian Francica, Thomas R. Nirschl, Ali Ghasemzadeh, Dimitrios Mathios, Sarah Harris-Bookman, Christopher C. Jackson, Christina Jackson, Xiaobu Ye, Phuoc T. Tran, Betty Tyler, Vladimir Coric, Mark Selby, Henry Brem, Charles G. Drake, Drew M. Pardoll, Michael Lim

Main menu

Table of contents

December 2016 - Volume 4 - 1

Basic Tumor Immunology

Case Report

Clinical Trials Monitor

Clinical/Translational Cancer Immunotherapy

Commentary

Editorial

Immunotherapy Biomarkers

Meeting Report

Position Articles and Guidelines

Review

Short Report

Reviewer Acknowledgement

Erratum

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

December 2016 - Volume 4 - 1

Basic Tumor Immunology

Case Report

Clinical Trials Monitor

Clinical/Translational Cancer Immunotherapy

Commentary

Editorial

Immunotherapy Biomarkers

Meeting Report

Position Articles and Guidelines

Review

Short Report

Reviewer Acknowledgement

Erratum